Prevention of nosocomial diarrhea using autostrains of lactobacilli isolated from wastewater and from the intestinal biotope of patients

Abstract

Introduction. The work is devoted to evaluating the results of own studies on the possibility of using autostrains of lactobacilli isolated from wastewater and the intestinal biotope of patients, based on their antagonistic properties to prevent of nosocomial diarrhea associated with toxigenic Clostridioides difficile. There are presented results of studies on an animal model of antibiotic-associated diarrhea to determine the effectiveness of lactobacilli when eliminating toxigenic C. difficile.
 Materials and methods. Studies were conducted on the antagonistic activity of clinical cultures of lactobacilli isolated from wastewater and intestinal biotope of patients against toxigenic strains of C. difficile isolated from patients with nosocomial diarrhea. Preclinical tests of the efficacy of the selected highly antagonistically active strain of Lactobacillus paracasei CTR079 in vivo were carried out in an animal model of C. difficile-associated infection in mice of the C57BL line.
 Results. As a result of the studies, lactobacilli with high, medium, and without antagonistic activity were isolated. Antagonistically inactive strains were unable to inhibit the growth of C. difficile, unlike highly active strains. A strain of Lactobacillus paracasei CTR079 was selected to study the possibility of its use as a probiotic strain for the prevention and treatment of C. difficile associated infection in an in vivo experiment. Various changes in the intestinal epithelium as a result of the development of C. difficile-associated infection. 
 Limitations of the study. As part of the study, all isolated strains of lactobacilli were identified and stored for the study of biological, genetic properties, and production of bacteriocins.
 Conclusion. As a result of the studies, the use of highly active strains of lactobacilli was established to be a promising direction for the prevention and treatment of nosocomial diarrhea, which will reduce the spread of C. difficile among patients and in the environment of medical institutions.